

Supplementary Materials

Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D₃/D₄ Receptors

Pradeep Paudel ¹, Su Hui Seong ¹, Sangwook Wu ², Suhyun Park ², Hyun Ah Jung ^{3,*} and Jae Sue Choi ^{1,*}

¹ Department of Food and Life Science, Pukyong National University, Busan 48513, Korea; phr.paudel@gmail.com (P.P.); seongsuhui@naver.com (S.H.S.)

² Department of Physics, Pukyong National University, Busan 48513, Korea; sangwoow@pknu.ac.kr (S.W.); psh7990@naver.com (S.P.)

³ Department of Food Science and Human Nutrition, Chonbuk National University, Jeonju 54896, Korea

* Correspondence: jungha@jbnu.ac.kr (H.A.J.); choijs@pknu.ac.kr (J.S.C.); Tel.: +82-63-270-4882 (H.A.J.); +82-51-629-5845 (J.S.C.)

Table S1. Experimental conditions for cell-based functional assays.

Assay/Receptor	Source	Stimulus	Incubation	Measured component	Detection method
D ₁ (<i>h</i>) Dopamine (agonist effect)	Human recombinant (CHO cells)	None (control: 10 μ M dopamine)	30 min RT	cAMP	HTRF
D ₁ (<i>h</i>) Dopamine (antagonist effect)	Human recombinant (CHO cells)	Dopamine (300 nM)	30 min RT	cAMP	HTRF
D ₃ (<i>h</i>) Dopamine (agonist effect)	Human recombinant (CHO cells)	None (control: 300 nM dopamine)	30 min 37 °C	cAMP	HTRF
D ₃ (<i>h</i>) Dopamine (antagonist effect)	Human recombinant (CHO cells)	Dopamine (10 nM)	30 min 37 °C	cAMP	HTRF
D ₄ (<i>h</i>) Dopamine (agonist effect)	Human recombinant (CHO cells)	None (control: 10 μ M dopamine)	10 min 37 °C	cAMP	HTRF
D ₄ (<i>h</i>) Dopamine (antagonist effect)	Human recombinant (CHO cells)	Dopamine (100 nM)	10 min 37 °C	cAMP	HTRF
M ₅ (<i>h</i>) Muscarinic (agonist effect)	Human recombinant (RBL cells)	None (control: 0.624 μ M ACh)	RT	Intracellular [Ca ²⁺]	Fluorimetry
M ₅ (<i>h</i>) Muscarinic (antagonist effect)	Human recombinant (RBL cells)	ACh (10 nM)	RT	Intracellular [Ca ²⁺]	Fluorimetry
NK ₁ (<i>h</i>) Tachykinin (agonist effect)	Human endogenous (U373MG cells)	None (control: 30 nM [Sar ⁹ , Met(O ₂) ¹¹]-SP)	RT	Intracellular [Ca ²⁺]	Fluorimetry
NK ₁ (<i>h</i>) Tachykinin (antagonist effect)	Human endogenous (U373MG cells)	[Sar ⁹ , Met(O ₂) ¹¹]-SP (1 nM)	RT	Intracellular [Ca ²⁺]	Fluorimetry
V _{1a} (<i>h</i>) Vasopressin / Oxytocin (agonist effect)	Human recombinant (CHO cells)	None (control: 1 μ M AVP)	RT	Intracellular [Ca ²⁺]	Fluorimetry
V _{1a} (<i>h</i>) Vasopressin / Oxytocin (antagonist effect)	Human recombinant (CHO cells)	AVP (10 nM)	RT	Intracellular [Ca ²⁺]	Fluorimetry
5-HT _{1A} (<i>h</i>) Serotonin (agonist effect)	Human recombinant (BA/F3 cells)	None (control: 2.5 μ M serotonin)	RT	Intracellular [Ca ²⁺]	Fluorimetry
5-HT _{1A} (<i>h</i>) Serotonin (antagonist effect)	Human recombinant (BA/F3 cells)	Serotonin (30 nM)	RT	Intracellular [Ca ²⁺]	Fluorimetry

HTRF: Homogeneous time-resolved fluorescence.




Figure S1. Molecular docking models for D₃R binding with positive controls, dopamine (A), reported agonist rotigotine (B), reported antagonists eticlopride (C) and (+)-butaclamol (D).




Figure S2. Molecular docking models for D₄R binding with positive controls, dopamine (A), reported agonist nemonapride (B), and reported antagonist CHEMBL332154 (C).